|
Video: What is a Stock Split?
|
|
Surface Oncology is an immuno-oncology company focused on using its knowledge of the biological pathways crucial to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation (CD) 73 and CD39, respectively, and illustrate how Co.'s knowledge of TME biology can be utilized across programs. SRF388 is an antibody targeting interleukin 27, an immunosuppressive cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. GSK4381562 is an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells. According to our SURF stock split history records, SURF has had 0 splits. | |
|
SURF (SURF) has 0 splits in our SURF stock split history database.
Looking at the SURF stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SURF shares, starting with a $10,000 purchase of SURF, presented on a split-history-adjusted basis factoring in the complete SURF stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/20/2018 |
|
End date: |
09/08/2023 |
|
Start price/share: |
$13.81 |
|
End price/share: |
$1.07 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-92.25% |
|
Average Annual Total Return: |
-37.79% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$774.65 |
|
Years: |
5.39 |
|
|
|
|
|